See more : NOV Inc. (NOV.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TBN Corporation Public Company Limited (TBN.BK) Income Statement Analysis – Financial Results
- Sparindex INDEX Nye Obl.mark Ak (SPVINOAKKKLA.CO) Income Statement Analysis – Financial Results
- AllianceBernstein Holding L.P. (AB) Income Statement Analysis – Financial Results
- FSE Lifestyle Services Limited (0331.HK) Income Statement Analysis – Financial Results
- Dongbu Corporation (005965.KS) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma partners with McQuade Center for Strategic Research and Development to develop psychedelic medicine
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced a collaboration with McQuade Center for Strategic Research and Development, LLC (MSRD)— a member of the global Otsuka family of pharmaceutical companies— to develop psychedelic medicine. MSRD has made a strategic investment to support the discovery...
Mindset Pharma recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has provided a recap of its 2021 milestones and highlights as the company expands its portfolio of next-generation psychedelic compounds. In a statement, Mindset CEO James Lanthier called 2021 “just the beginning” for the company.
Mindset Pharma leading the charge to advance psychedelic medicines to treat mental illness
One in four people in the world will be affected by mental or neurological disorders in lifetime Focused on the medical psychedelic market Market needs a source of high quality and low-cost psilocybin What Mindset Pharma does: Mindset Pharma Inc...
Mindset Pharma files international patent application covering its Family 3 psychedelic compounds
Mindset Pharma Inc. (CSE:MSET, OTCQB:MSSTF) announced it has filed an international patent application covering its Family 3 novel psychedelic compounds. The company's Family 3 consists of certain compounds that have demonstrated half-lives extending well beyond those exhibited by comparable classical psychedelic...
Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma is pursuing breakthroughs in the psychedelics field with the help of “hard science”
Psychedelic drug researchers have moved mountains over the last 30 years, helping to show that these misunderstood substances have vast potential to benefit people, while being safe and non-addictive. Today, psilocybin is in Phase 2b clinical trials, MDMA is in...
Mindset Pharma announces poster presentation on lead candidate at Society for Neuroscience meeting
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), the psychedelic medicines-focused group, revealed that a poster on its lead compound MSP-1014 will be presented at the prestigious Society for Neuroscience (SFN) 50th Annual Meeting: Neuroscience 2021, being held virtually this year. In focus will...
HC Wainright & Co starts coverage on Mindset Pharma with a Buy rating and C$5 price target
HC Wainwright & Co has started coverage on psychedelics firm Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) with a 'Buy' rating and a C$5 price target. The Canadian company is advancing psychedelic-based treatments using a rigorous scientific process through clinical trials.
HC Wainright & Co starts covering Mindset Pharma with a Buy rating and C$5 price target
HC Wainwright & Co has started coverage on psychedelics firm Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) with a 'Buy' rating and a C$5 price target. The Canadian company is advancing psychedelic-based treatments using a rigorous scientific process through clinical trials.
HC Wainright & Co starts coverage of Mindset Pharma with a Buy rating and C$5 price target
HC Wainwright & Co has started coverage on psychedelics firm Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) with a 'Buy' rating and a C$5 price target. The Canadian company is advancing psychedelic-based treatments using a rigorous scientific process through clinical trials.
Source: https://incomestatements.info
Category: Stock Reports